TCA Global commits to buy company's common shares over two-year term
By Devika Patel
Knoxville, Tenn., July 18 - Puramed Bioscience Inc. negotiated a $2 million two-year committed equity facility with TCA Global Credit Master Fund, LP on July 11, according to an 8-K filed Wednesday with the Securities and Exchange Commission.
The price per share will be equal to 95% of the lowest daily volume weighted average price of the company's common stock during the five consecutive trading days following an advance notice.
TCA also will receive a $115,000 facility fee.
Based in Schofield, Wisc., Puramed BioScience develops and markets a line of non-prescription medicinal or healthcare products.
| Issuer: | Puramed Bioscience Inc.
|
| Issue: | Committed equity facility
|
| Amount: | $2 million
|
| Tenor: | Two years
|
| Price: | 95% of the lowest daily volume weighted average price of the company's common stock during the five consecutive trading days following an advance notice
|
| Warrants: | No
|
| Investor: | TCA Global Credit Master Fund, LP
|
| Fees: | $115,000
|
| Pricing date: | July 11
|
| Stock symbol: | OTCBB: PMBS
|
| Stock price: | $0.15 at close July 10
|
| Market capitalization: | $5.36 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
